|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Gynecologic oncologists involvement on ovarian cancer standard of care receipt and survival显示文摘AIM:To examine the influence of gynecologic oncolo-gists(GO) in the United States on surgical/chemotherapeutic standard of care(SOC), and how this translates into improved survival among women with ovarian cancer(OC).METHODS: Surveillance, Epidemiology, and End Result(SEER)-Medicare data were used to identify 11688 OC patients(1992-2006). Only Medicare recipients with an initial surgical procedure code(n = 6714) were included. Physician specialty was identified by linking SEER-Medicare to the American Medical Association Masterfile. SOC was defined by a panel of GOs. Multivariate logistic regression was used to determine predictors of receiving surgical/chemotherapeutic SOCand proportional hazards modeling to estimate the effect of SOC treatment and physician specialty on survival. RESULTS: About 34% received surgery from a GO and 25% received the overall SOC. One-third of women had a GO involved sometime during their care. Women receiving surgery from a GO vs non-GO had 2.35 times the odds of receiving the surgical SOC and 1.25 times the odds of receiving chemotherapeutic SOC(P < 0.01). Risk of mortality was greater among women not receiving surgical SOC compared to those who did [hazard ratio = 1.22(95%CI: 1.12-1.33), P < 0.01], and also was higher among women seen by non-GOs vs GOs(for surgical treatment) after adjusting for covariates. Median survival time was 14 mo longer for women receiving combined SOC. CONCLUSION: A survival advantage associated with receiving surgical SOC and overall treatment by a GO is supported. Persistent survival differences, particularly among those not receiving the SOC, require further investigation. | Sun Hee Rim Shawn Hirsch Cheryll C Thomas Wendy R Brewster Darryl Cooney Trevor D Thompson Sherri L Stewart | 2016 | World Journal of Obstetrics and Gynecology2016，5，2： | 3 |
| 2 | Severe Hand, Foot, and Mouth Disease Associated with Coxsackievirus A6 - Alabama, Connecticut, California, and Nevada, November 201 1 - February 2012显示文摘 | McIntyre Mary G Stevens Kelly M Davidson Sherri Pippin Tina Magill Dagny Kulhanjian Julie A Kelly Daniel Greenhow Tara L Salas Maria L Yagi Shigeo Padilla Tasha Berumen Ricardo Glaser Carol Landry Marie Louise Lott Jason Chen Lei Paulson | 2012 | EN2012，，12： | 2 |
| 3 | A randomized trial of bevaci-zumab,an anti-vascular endothelial growth factor antibody,for meta-static renal cancer显示文摘 | Yang JC Haworth L Sherry RM | | 0，，： | 1 |
| 4 | Differential effects of angiotensin 1] on cardiac cell proliferation and intramyocardial perivascular fibrosis in vivo显示文摘 | McEwan PE Gray GA Sherry L | 1998 | Circulation1998，98，24： | 1 |
| 5 | Biofilms formed by Candida albicans bloodstream isolates display phenotypic and transcriptional heterogeneity that are associated with resistance and pathogenicity显示文摘 | Sherry L Rajendran R Lappin DF | 2014 | BMC Microbiology2014，14，： | 1 |
| 6 | Growth response of selected vegetable crops to spent mushroom compost appli- cation in a controlled environment显示文摘 | SHERRY I-I W VIRGINIA I L DAVID L C | 1984 | Plant and Soi11984，82，1： | 1 |
| 7 | Physiological predictors of survival during high-frequency oscillatory ventilation in a- dults with acute respiratory distress syndrome 显示文摘 | Camporota L Sherry T Smith J | 2013 | Crit Care2013，17，2： | 1 |
| 8 | A randomized trial of bevacizumab,an anti-VEGF antibody,for metastatic renal cancer显示文摘 | Yang JC Haworth L Sherry RM | 2003 | N Engl J Med2003，349，5： | 1 |
| 9 | The phase II urokinase-streptokinase pulmonary embolism trial: a national cooperative study显示文摘 | Sasahra A A Bell W R Simon T L Stengle J M Sherry S | 1975 | Thromb Diath Haemorrh1975，33，： | 1 |
| 10 | A randomized trial 9f bevacizumab,an anti-vascular endothelial growth factor tntibody,for metastatic renal cancer显示文摘 | Yang JC Haworth L Sherry RM et a/ | 2003 | N Engl J Med2003，349，5： | 1 |
| 11 | A randomized trial of beva- ci-zumab, ananti-vascular endothelial growth factor antibody, for meta- static renal cancer显示文摘 | Yang JC Haworth L Sherry RM | 2003 | N Engl J Med2003，349，5： | 1 |
| 12 | PPAR regulates the antiinflammatory effects of carbon monoxide on macrophages:a ene profiling Study显示文摘 | Martin Bilban Sherrie L | 2004 | Blood (ASH Annual Meeting Abstracts)2004，104，： | 1 |
| 13 | Long-Term micro- and maeroeireulatory measurements in conscious rats 显示文摘 | THOMAS L S SHERRIE W O PHILLIP M H | 1985 | Microvascular Research1985，29，： | 1 |
| 14 | A randomized trial ofbevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer显示文摘 | Yang JC Haworth L Sherry RM | 2003 | N Engl J Med2003，349，5： | 1 |
| 15 | A randomized trial of bevacizumab, an anti-vascular endothelial growth factor antibody, for metastatic renal cancer显示文摘 | Yang JC Haworth L Sherry RM | 2003 | N Engl J Med2003，349，5： | 1 |
| 16 | Biofilm formation is a risk factor for mortality in patients with Candida albicans bloodstream infection-Scotland,2012-2013显示文摘 | Rajendran R Sherry L Nile CJ | 2016 | Clin Microbiol Infect2016，22，1： | 1 |
| 17 | A randomized trial of bevaeizumab, an anti-vascular endothelial growth factor an- tibody, for metastatic renal cancer显示文摘 | Yang JC Haworth L Sherry RM | 2003 | N Engl J M ed2003，349，5： | 1 |
| 18 | Evaluation of the MicroSeq system for identification of myeohacteria by 16S ribosomal DNA sequencing and its integration into a routine ehnieal mycobacteriology laboratory显示文摘 | Leslie Hall Kelly A Doerr Sherri L Wohlfiel | 2003 | Journal of Clinical Microbiology2003，41，4： | 1 |
| 19 | Growth response of selected vegetable crops to spent mushroom compost application in a controlled environment显示文摘 | SHERRY HSIAO L W VIRGINIA I | 1984 | Plant and Soil1984，82，： | 1 |
| 20 | Cost-effectiveness anaysis of extended conservative therapy versus surgical intervention in the management of hemiated lumbar intervertebral disc 显示文摘 | Schvartzman L Weingarten E Sherry H | 1992 | Spine1992，17，2： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员